nodes	percent_of_prediction	percent_of_DWPC	metapath
Emtricitabine—Nucleoside Analog—Azathioprine—systemic scleroderma	0.871	1	CiPCiCtD
Emtricitabine—DCK—Desoximetasone—Mometasone—systemic scleroderma	0.000787	0.328	CbGdCrCtD
Emtricitabine—DCK—Diflorasone—Mometasone—systemic scleroderma	0.000764	0.319	CbGdCrCtD
Emtricitabine—DCK—Desoximetasone—Prednisone—systemic scleroderma	0.000429	0.179	CbGdCrCtD
Emtricitabine—DCK—Diflorasone—Prednisone—systemic scleroderma	0.000416	0.174	CbGdCrCtD
Emtricitabine—Arthralgia—Mycophenolic acid—systemic scleroderma	0.000155	0.00122	CcSEcCtD
Emtricitabine—Myalgia—Mycophenolic acid—systemic scleroderma	0.000155	0.00122	CcSEcCtD
Emtricitabine—Infection—Leflunomide—systemic scleroderma	0.000154	0.00122	CcSEcCtD
Emtricitabine—Gastrointestinal pain—Captopril—systemic scleroderma	0.000154	0.00122	CcSEcCtD
Emtricitabine—Anxiety—Mycophenolic acid—systemic scleroderma	0.000154	0.00122	CcSEcCtD
Emtricitabine—Asthenia—Mometasone—systemic scleroderma	0.000154	0.00122	CcSEcCtD
Emtricitabine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.000153	0.00121	CcSEcCtD
Emtricitabine—Polyuria—Methotrexate—systemic scleroderma	0.000153	0.00121	CcSEcCtD
Emtricitabine—Nervous system disorder—Leflunomide—systemic scleroderma	0.000152	0.0012	CcSEcCtD
Emtricitabine—Thrombocytopenia—Leflunomide—systemic scleroderma	0.000152	0.0012	CcSEcCtD
Emtricitabine—Pruritus—Mometasone—systemic scleroderma	0.000152	0.0012	CcSEcCtD
Emtricitabine—Anaemia—Lisinopril—systemic scleroderma	0.000151	0.00119	CcSEcCtD
Emtricitabine—Skin disorder—Leflunomide—systemic scleroderma	0.000151	0.00119	CcSEcCtD
Emtricitabine—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.00015	0.00118	CcSEcCtD
Emtricitabine—Angioedema—Lisinopril—systemic scleroderma	0.000149	0.00118	CcSEcCtD
Emtricitabine—Abdominal pain—Captopril—systemic scleroderma	0.000149	0.00118	CcSEcCtD
Emtricitabine—Body temperature increased—Captopril—systemic scleroderma	0.000149	0.00118	CcSEcCtD
Emtricitabine—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000148	0.00117	CcSEcCtD
Emtricitabine—Nausea—Pentoxifylline—systemic scleroderma	0.000148	0.00117	CcSEcCtD
Emtricitabine—Infection—Mycophenolic acid—systemic scleroderma	0.000147	0.00116	CcSEcCtD
Emtricitabine—Diarrhoea—Mometasone—systemic scleroderma	0.000147	0.00116	CcSEcCtD
Emtricitabine—Hypokalaemia—Prednisone—systemic scleroderma	0.000147	0.00116	CcSEcCtD
Emtricitabine—Renal failure acute—Methotrexate—systemic scleroderma	0.000146	0.00115	CcSEcCtD
Emtricitabine—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000145	0.00115	CcSEcCtD
Emtricitabine—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.000145	0.00115	CcSEcCtD
Emtricitabine—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.000144	0.00114	CcSEcCtD
Emtricitabine—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000144	0.00114	CcSEcCtD
Emtricitabine—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.000143	0.00113	CcSEcCtD
Emtricitabine—Cough—Lisinopril—systemic scleroderma	0.000143	0.00113	CcSEcCtD
Emtricitabine—Alanine aminotransferase increased—Prednisone—systemic scleroderma	0.000142	0.00112	CcSEcCtD
Emtricitabine—Muscular weakness—Prednisone—systemic scleroderma	0.000142	0.00112	CcSEcCtD
Emtricitabine—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000142	0.00112	CcSEcCtD
Emtricitabine—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000141	0.00112	CcSEcCtD
Emtricitabine—Insomnia—Leflunomide—systemic scleroderma	0.00014	0.00111	CcSEcCtD
Emtricitabine—Paraesthesia—Leflunomide—systemic scleroderma	0.000139	0.0011	CcSEcCtD
Emtricitabine—Arthralgia—Lisinopril—systemic scleroderma	0.000139	0.0011	CcSEcCtD
Emtricitabine—Myalgia—Lisinopril—systemic scleroderma	0.000139	0.0011	CcSEcCtD
Emtricitabine—Anxiety—Lisinopril—systemic scleroderma	0.000139	0.0011	CcSEcCtD
Emtricitabine—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000139	0.00109	CcSEcCtD
Emtricitabine—Dyspnoea—Leflunomide—systemic scleroderma	0.000138	0.00109	CcSEcCtD
Emtricitabine—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000138	0.00109	CcSEcCtD
Emtricitabine—Dyspepsia—Leflunomide—systemic scleroderma	0.000137	0.00108	CcSEcCtD
Emtricitabine—Pancreatitis—Prednisone—systemic scleroderma	0.000137	0.00108	CcSEcCtD
Emtricitabine—Vomiting—Mometasone—systemic scleroderma	0.000136	0.00108	CcSEcCtD
Emtricitabine—Rash—Mometasone—systemic scleroderma	0.000135	0.00107	CcSEcCtD
Emtricitabine—Asthenia—Captopril—systemic scleroderma	0.000135	0.00107	CcSEcCtD
Emtricitabine—Dermatitis—Mometasone—systemic scleroderma	0.000135	0.00107	CcSEcCtD
Emtricitabine—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000135	0.00107	CcSEcCtD
Emtricitabine—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000134	0.00106	CcSEcCtD
Emtricitabine—Headache—Mometasone—systemic scleroderma	0.000134	0.00106	CcSEcCtD
Emtricitabine—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000134	0.00106	CcSEcCtD
Emtricitabine—Insomnia—Mycophenolic acid—systemic scleroderma	0.000134	0.00106	CcSEcCtD
Emtricitabine—Fatigue—Leflunomide—systemic scleroderma	0.000134	0.00106	CcSEcCtD
Emtricitabine—Pruritus—Captopril—systemic scleroderma	0.000133	0.00105	CcSEcCtD
Emtricitabine—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000133	0.00105	CcSEcCtD
Emtricitabine—Pain—Leflunomide—systemic scleroderma	0.000133	0.00105	CcSEcCtD
Emtricitabine—Infection—Lisinopril—systemic scleroderma	0.000133	0.00105	CcSEcCtD
Emtricitabine—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000132	0.00105	CcSEcCtD
Emtricitabine—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000132	0.00104	CcSEcCtD
Emtricitabine—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000131	0.00103	CcSEcCtD
Emtricitabine—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000131	0.00103	CcSEcCtD
Emtricitabine—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.00013	0.00103	CcSEcCtD
Emtricitabine—Neutropenia—Prednisone—systemic scleroderma	0.00013	0.00103	CcSEcCtD
Emtricitabine—Abdominal pain—Azathioprine—systemic scleroderma	0.00013	0.00103	CcSEcCtD
Emtricitabine—Body temperature increased—Azathioprine—systemic scleroderma	0.00013	0.00103	CcSEcCtD
Emtricitabine—Skin disorder—Lisinopril—systemic scleroderma	0.00013	0.00102	CcSEcCtD
Emtricitabine—Diarrhoea—Captopril—systemic scleroderma	0.000129	0.00102	CcSEcCtD
Emtricitabine—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000128	0.00101	CcSEcCtD
Emtricitabine—Fatigue—Mycophenolic acid—systemic scleroderma	0.000128	0.00101	CcSEcCtD
Emtricitabine—Nausea—Mometasone—systemic scleroderma	0.000127	0.00101	CcSEcCtD
Emtricitabine—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000127	0.001	CcSEcCtD
Emtricitabine—Pain—Mycophenolic acid—systemic scleroderma	0.000127	0.001	CcSEcCtD
Emtricitabine—Weight decreased—Prednisone—systemic scleroderma	0.000126	0.000996	CcSEcCtD
Emtricitabine—Hyperglycaemia—Prednisone—systemic scleroderma	0.000126	0.000993	CcSEcCtD
Emtricitabine—Cough—Mycophenolate mofetil—systemic scleroderma	0.000125	0.000987	CcSEcCtD
Emtricitabine—Dizziness—Captopril—systemic scleroderma	0.000125	0.000984	CcSEcCtD
Emtricitabine—Depression—Prednisone—systemic scleroderma	0.000124	0.000979	CcSEcCtD
Emtricitabine—Urticaria—Leflunomide—systemic scleroderma	0.000123	0.000974	CcSEcCtD
Emtricitabine—Abdominal pain—Leflunomide—systemic scleroderma	0.000123	0.00097	CcSEcCtD
Emtricitabine—Body temperature increased—Leflunomide—systemic scleroderma	0.000123	0.00097	CcSEcCtD
Emtricitabine—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000122	0.000963	CcSEcCtD
Emtricitabine—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000122	0.000963	CcSEcCtD
Emtricitabine—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000122	0.000962	CcSEcCtD
Emtricitabine—Breast disorder—Methotrexate—systemic scleroderma	0.000122	0.000962	CcSEcCtD
Emtricitabine—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000122	0.00096	CcSEcCtD
Emtricitabine—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000122	0.00096	CcSEcCtD
Emtricitabine—Hypersensitivity—Azathioprine—systemic scleroderma	0.000121	0.000957	CcSEcCtD
Emtricitabine—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000121	0.000957	CcSEcCtD
Emtricitabine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000121	0.000957	CcSEcCtD
Emtricitabine—Insomnia—Lisinopril—systemic scleroderma	0.000121	0.000953	CcSEcCtD
Emtricitabine—Paraesthesia—Lisinopril—systemic scleroderma	0.00012	0.000946	CcSEcCtD
Emtricitabine—Vomiting—Captopril—systemic scleroderma	0.00012	0.000946	CcSEcCtD
Emtricitabine—Dyspnoea—Lisinopril—systemic scleroderma	0.000119	0.00094	CcSEcCtD
Emtricitabine—Rash—Captopril—systemic scleroderma	0.000119	0.000938	CcSEcCtD
Emtricitabine—Dermatitis—Captopril—systemic scleroderma	0.000119	0.000937	CcSEcCtD
Emtricitabine—Headache—Captopril—systemic scleroderma	0.000118	0.000932	CcSEcCtD
Emtricitabine—Dyspepsia—Lisinopril—systemic scleroderma	0.000117	0.000928	CcSEcCtD
Emtricitabine—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000117	0.000925	CcSEcCtD
Emtricitabine—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000117	0.000925	CcSEcCtD
Emtricitabine—Infection—Mycophenolate mofetil—systemic scleroderma	0.000116	0.000917	CcSEcCtD
Emtricitabine—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000115	0.00091	CcSEcCtD
Emtricitabine—Fatigue—Lisinopril—systemic scleroderma	0.000115	0.000909	CcSEcCtD
Emtricitabine—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000115	0.000905	CcSEcCtD
Emtricitabine—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000114	0.000904	CcSEcCtD
Emtricitabine—Hypersensitivity—Leflunomide—systemic scleroderma	0.000114	0.000904	CcSEcCtD
Emtricitabine—Pancreatitis—Methotrexate—systemic scleroderma	0.000114	0.000902	CcSEcCtD
Emtricitabine—Pain—Lisinopril—systemic scleroderma	0.000114	0.000901	CcSEcCtD
Emtricitabine—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000114	0.000897	CcSEcCtD
Emtricitabine—Diarrhoea—Azathioprine—systemic scleroderma	0.000113	0.000889	CcSEcCtD
Emtricitabine—Nausea—Captopril—systemic scleroderma	0.000112	0.000884	CcSEcCtD
Emtricitabine—Asthenia—Leflunomide—systemic scleroderma	0.000111	0.00088	CcSEcCtD
Emtricitabine—Pruritus—Leflunomide—systemic scleroderma	0.00011	0.000868	CcSEcCtD
Emtricitabine—Connective tissue disorder—Prednisone—systemic scleroderma	0.00011	0.000866	CcSEcCtD
Emtricitabine—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000109	0.000862	CcSEcCtD
Emtricitabine—Neutropenia—Methotrexate—systemic scleroderma	0.000109	0.00086	CcSEcCtD
Emtricitabine—Dizziness—Azathioprine—systemic scleroderma	0.000109	0.000859	CcSEcCtD
Emtricitabine—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000108	0.000855	CcSEcCtD
Emtricitabine—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000107	0.000841	CcSEcCtD
Emtricitabine—Asthenia—Mycophenolic acid—systemic scleroderma	0.000106	0.000839	CcSEcCtD
Emtricitabine—Diarrhoea—Leflunomide—systemic scleroderma	0.000106	0.000839	CcSEcCtD
Emtricitabine—Urticaria—Lisinopril—systemic scleroderma	0.000106	0.000837	CcSEcCtD
Emtricitabine—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000106	0.000835	CcSEcCtD
Emtricitabine—Abdominal pain—Lisinopril—systemic scleroderma	0.000105	0.000833	CcSEcCtD
Emtricitabine—Body temperature increased—Lisinopril—systemic scleroderma	0.000105	0.000833	CcSEcCtD
Emtricitabine—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000105	0.000829	CcSEcCtD
Emtricitabine—Pruritus—Mycophenolic acid—systemic scleroderma	0.000105	0.000828	CcSEcCtD
Emtricitabine—Vomiting—Azathioprine—systemic scleroderma	0.000105	0.000826	CcSEcCtD
Emtricitabine—Pneumonia—Methotrexate—systemic scleroderma	0.000104	0.000825	CcSEcCtD
Emtricitabine—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000104	0.000823	CcSEcCtD
Emtricitabine—Infestation NOS—Methotrexate—systemic scleroderma	0.000104	0.00082	CcSEcCtD
Emtricitabine—Infestation—Methotrexate—systemic scleroderma	0.000104	0.00082	CcSEcCtD
Emtricitabine—Rash—Azathioprine—systemic scleroderma	0.000104	0.000819	CcSEcCtD
Emtricitabine—Dermatitis—Azathioprine—systemic scleroderma	0.000104	0.000818	CcSEcCtD
Emtricitabine—Depression—Methotrexate—systemic scleroderma	0.000104	0.000818	CcSEcCtD
Emtricitabine—Headache—Azathioprine—systemic scleroderma	0.000103	0.000814	CcSEcCtD
Emtricitabine—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000103	0.000813	CcSEcCtD
Emtricitabine—Dizziness—Leflunomide—systemic scleroderma	0.000103	0.000811	CcSEcCtD
Emtricitabine—Renal failure—Methotrexate—systemic scleroderma	0.000102	0.000806	CcSEcCtD
Emtricitabine—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000101	0.000801	CcSEcCtD
Emtricitabine—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000101	0.000797	CcSEcCtD
Emtricitabine—Immune system disorder—Prednisone—systemic scleroderma	0.000101	0.000796	CcSEcCtD
Emtricitabine—Pain—Mycophenolate mofetil—systemic scleroderma	0.0001	0.00079	CcSEcCtD
Emtricitabine—Haematuria—Methotrexate—systemic scleroderma	9.9e-05	0.000782	CcSEcCtD
Emtricitabine—Vomiting—Leflunomide—systemic scleroderma	9.87e-05	0.00078	CcSEcCtD
Emtricitabine—Hypersensitivity—Lisinopril—systemic scleroderma	9.83e-05	0.000776	CcSEcCtD
Emtricitabine—Hepatobiliary disease—Methotrexate—systemic scleroderma	9.82e-05	0.000776	CcSEcCtD
Emtricitabine—Dizziness—Mycophenolic acid—systemic scleroderma	9.8e-05	0.000774	CcSEcCtD
Emtricitabine—Rash—Leflunomide—systemic scleroderma	9.79e-05	0.000773	CcSEcCtD
Emtricitabine—Dermatitis—Leflunomide—systemic scleroderma	9.78e-05	0.000773	CcSEcCtD
Emtricitabine—Mental disorder—Prednisone—systemic scleroderma	9.77e-05	0.000772	CcSEcCtD
Emtricitabine—Nausea—Azathioprine—systemic scleroderma	9.77e-05	0.000771	CcSEcCtD
Emtricitabine—Headache—Leflunomide—systemic scleroderma	9.73e-05	0.000768	CcSEcCtD
Emtricitabine—Malnutrition—Prednisone—systemic scleroderma	9.71e-05	0.000767	CcSEcCtD
Emtricitabine—Asthenia—Lisinopril—systemic scleroderma	9.57e-05	0.000756	CcSEcCtD
Emtricitabine—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	9.56e-05	0.000755	CcSEcCtD
Emtricitabine—Pruritus—Lisinopril—systemic scleroderma	9.44e-05	0.000746	CcSEcCtD
Emtricitabine—Vomiting—Mycophenolic acid—systemic scleroderma	9.42e-05	0.000744	CcSEcCtD
Emtricitabine—Rash—Mycophenolic acid—systemic scleroderma	9.34e-05	0.000738	CcSEcCtD
Emtricitabine—Dermatitis—Mycophenolic acid—systemic scleroderma	9.33e-05	0.000737	CcSEcCtD
Emtricitabine—Hepatitis—Methotrexate—systemic scleroderma	9.32e-05	0.000736	CcSEcCtD
Emtricitabine—Urticaria—Mycophenolate mofetil—systemic scleroderma	9.29e-05	0.000734	CcSEcCtD
Emtricitabine—Headache—Mycophenolic acid—systemic scleroderma	9.28e-05	0.000733	CcSEcCtD
Emtricitabine—Pharyngitis—Methotrexate—systemic scleroderma	9.25e-05	0.000731	CcSEcCtD
Emtricitabine—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	9.24e-05	0.00073	CcSEcCtD
Emtricitabine—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	9.24e-05	0.00073	CcSEcCtD
Emtricitabine—Nausea—Leflunomide—systemic scleroderma	9.23e-05	0.000728	CcSEcCtD
Emtricitabine—Urinary tract disorder—Methotrexate—systemic scleroderma	9.21e-05	0.000727	CcSEcCtD
Emtricitabine—Urethral disorder—Methotrexate—systemic scleroderma	9.14e-05	0.000722	CcSEcCtD
Emtricitabine—Diarrhoea—Lisinopril—systemic scleroderma	9.13e-05	0.000721	CcSEcCtD
Emtricitabine—Anaemia—Prednisone—systemic scleroderma	8.98e-05	0.000709	CcSEcCtD
Emtricitabine—Angioedema—Prednisone—systemic scleroderma	8.87e-05	0.000701	CcSEcCtD
Emtricitabine—Dizziness—Lisinopril—systemic scleroderma	8.82e-05	0.000697	CcSEcCtD
Emtricitabine—Nausea—Mycophenolic acid—systemic scleroderma	8.8e-05	0.000695	CcSEcCtD
Emtricitabine—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	8.61e-05	0.00068	CcSEcCtD
Emtricitabine—Vomiting—Lisinopril—systemic scleroderma	8.49e-05	0.00067	CcSEcCtD
Emtricitabine—Immune system disorder—Methotrexate—systemic scleroderma	8.42e-05	0.000665	CcSEcCtD
Emtricitabine—Rash—Lisinopril—systemic scleroderma	8.41e-05	0.000664	CcSEcCtD
Emtricitabine—Dermatitis—Lisinopril—systemic scleroderma	8.41e-05	0.000664	CcSEcCtD
Emtricitabine—Mediastinal disorder—Methotrexate—systemic scleroderma	8.4e-05	0.000664	CcSEcCtD
Emtricitabine—Asthenia—Mycophenolate mofetil—systemic scleroderma	8.39e-05	0.000662	CcSEcCtD
Emtricitabine—Headache—Lisinopril—systemic scleroderma	8.36e-05	0.00066	CcSEcCtD
Emtricitabine—Pruritus—Mycophenolate mofetil—systemic scleroderma	8.27e-05	0.000653	CcSEcCtD
Emtricitabine—Myalgia—Prednisone—systemic scleroderma	8.27e-05	0.000653	CcSEcCtD
Emtricitabine—Arthralgia—Prednisone—systemic scleroderma	8.27e-05	0.000653	CcSEcCtD
Emtricitabine—Anxiety—Prednisone—systemic scleroderma	8.24e-05	0.000651	CcSEcCtD
Emtricitabine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	8.21e-05	0.000648	CcSEcCtD
Emtricitabine—Mental disorder—Methotrexate—systemic scleroderma	8.17e-05	0.000645	CcSEcCtD
Emtricitabine—Malnutrition—Methotrexate—systemic scleroderma	8.12e-05	0.000641	CcSEcCtD
Emtricitabine—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	8e-05	0.000632	CcSEcCtD
Emtricitabine—Nausea—Lisinopril—systemic scleroderma	7.93e-05	0.000626	CcSEcCtD
Emtricitabine—Infection—Prednisone—systemic scleroderma	7.87e-05	0.000622	CcSEcCtD
Emtricitabine—Back pain—Methotrexate—systemic scleroderma	7.85e-05	0.00062	CcSEcCtD
Emtricitabine—Nervous system disorder—Prednisone—systemic scleroderma	7.77e-05	0.000614	CcSEcCtD
Emtricitabine—Dizziness—Mycophenolate mofetil—systemic scleroderma	7.73e-05	0.000611	CcSEcCtD
Emtricitabine—Skin disorder—Prednisone—systemic scleroderma	7.7e-05	0.000608	CcSEcCtD
Emtricitabine—Anaemia—Methotrexate—systemic scleroderma	7.5e-05	0.000592	CcSEcCtD
Emtricitabine—Vomiting—Mycophenolate mofetil—systemic scleroderma	7.43e-05	0.000587	CcSEcCtD
Emtricitabine—Rash—Mycophenolate mofetil—systemic scleroderma	7.37e-05	0.000582	CcSEcCtD
Emtricitabine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	7.37e-05	0.000582	CcSEcCtD
Emtricitabine—Headache—Mycophenolate mofetil—systemic scleroderma	7.33e-05	0.000578	CcSEcCtD
Emtricitabine—Musculoskeletal discomfort—Prednisone—systemic scleroderma	7.22e-05	0.00057	CcSEcCtD
Emtricitabine—Insomnia—Prednisone—systemic scleroderma	7.17e-05	0.000566	CcSEcCtD
Emtricitabine—Paraesthesia—Prednisone—systemic scleroderma	7.12e-05	0.000562	CcSEcCtD
Emtricitabine—Cough—Methotrexate—systemic scleroderma	7.08e-05	0.000559	CcSEcCtD
Emtricitabine—Dyspepsia—Prednisone—systemic scleroderma	6.98e-05	0.000551	CcSEcCtD
Emtricitabine—Nausea—Mycophenolate mofetil—systemic scleroderma	6.95e-05	0.000548	CcSEcCtD
Emtricitabine—Myalgia—Methotrexate—systemic scleroderma	6.91e-05	0.000546	CcSEcCtD
Emtricitabine—Arthralgia—Methotrexate—systemic scleroderma	6.91e-05	0.000546	CcSEcCtD
Emtricitabine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	6.86e-05	0.000542	CcSEcCtD
Emtricitabine—Fatigue—Prednisone—systemic scleroderma	6.83e-05	0.00054	CcSEcCtD
Emtricitabine—Infection—Methotrexate—systemic scleroderma	6.58e-05	0.00052	CcSEcCtD
Emtricitabine—Nervous system disorder—Methotrexate—systemic scleroderma	6.5e-05	0.000513	CcSEcCtD
Emtricitabine—Thrombocytopenia—Methotrexate—systemic scleroderma	6.49e-05	0.000512	CcSEcCtD
Emtricitabine—Gastrointestinal pain—Prednisone—systemic scleroderma	6.48e-05	0.000512	CcSEcCtD
Emtricitabine—Skin disorder—Methotrexate—systemic scleroderma	6.43e-05	0.000508	CcSEcCtD
Emtricitabine—Urticaria—Prednisone—systemic scleroderma	6.3e-05	0.000497	CcSEcCtD
Emtricitabine—Abdominal pain—Prednisone—systemic scleroderma	6.27e-05	0.000495	CcSEcCtD
Emtricitabine—Body temperature increased—Prednisone—systemic scleroderma	6.27e-05	0.000495	CcSEcCtD
Emtricitabine—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	6.03e-05	0.000477	CcSEcCtD
Emtricitabine—Insomnia—Methotrexate—systemic scleroderma	5.99e-05	0.000473	CcSEcCtD
Emtricitabine—Paraesthesia—Methotrexate—systemic scleroderma	5.95e-05	0.00047	CcSEcCtD
Emtricitabine—Dyspnoea—Methotrexate—systemic scleroderma	5.91e-05	0.000466	CcSEcCtD
Emtricitabine—Hypersensitivity—Prednisone—systemic scleroderma	5.84e-05	0.000461	CcSEcCtD
Emtricitabine—Dyspepsia—Methotrexate—systemic scleroderma	5.83e-05	0.00046	CcSEcCtD
Emtricitabine—Gastrointestinal disorder—Methotrexate—systemic scleroderma	5.72e-05	0.000452	CcSEcCtD
Emtricitabine—Fatigue—Methotrexate—systemic scleroderma	5.71e-05	0.000451	CcSEcCtD
Emtricitabine—Asthenia—Prednisone—systemic scleroderma	5.69e-05	0.000449	CcSEcCtD
Emtricitabine—Pain—Methotrexate—systemic scleroderma	5.66e-05	0.000447	CcSEcCtD
Emtricitabine—Pruritus—Prednisone—systemic scleroderma	5.61e-05	0.000443	CcSEcCtD
Emtricitabine—Diarrhoea—Prednisone—systemic scleroderma	5.42e-05	0.000428	CcSEcCtD
Emtricitabine—Gastrointestinal pain—Methotrexate—systemic scleroderma	5.42e-05	0.000428	CcSEcCtD
Emtricitabine—Urticaria—Methotrexate—systemic scleroderma	5.26e-05	0.000416	CcSEcCtD
Emtricitabine—Dizziness—Prednisone—systemic scleroderma	5.24e-05	0.000414	CcSEcCtD
Emtricitabine—Abdominal pain—Methotrexate—systemic scleroderma	5.24e-05	0.000413	CcSEcCtD
Emtricitabine—Body temperature increased—Methotrexate—systemic scleroderma	5.24e-05	0.000413	CcSEcCtD
Emtricitabine—Vomiting—Prednisone—systemic scleroderma	5.04e-05	0.000398	CcSEcCtD
Emtricitabine—Rash—Prednisone—systemic scleroderma	5e-05	0.000395	CcSEcCtD
Emtricitabine—Dermatitis—Prednisone—systemic scleroderma	4.99e-05	0.000394	CcSEcCtD
Emtricitabine—Headache—Prednisone—systemic scleroderma	4.97e-05	0.000392	CcSEcCtD
Emtricitabine—Hypersensitivity—Methotrexate—systemic scleroderma	4.88e-05	0.000385	CcSEcCtD
Emtricitabine—Asthenia—Methotrexate—systemic scleroderma	4.75e-05	0.000375	CcSEcCtD
Emtricitabine—Nausea—Prednisone—systemic scleroderma	4.71e-05	0.000372	CcSEcCtD
Emtricitabine—Pruritus—Methotrexate—systemic scleroderma	4.69e-05	0.00037	CcSEcCtD
Emtricitabine—Diarrhoea—Methotrexate—systemic scleroderma	4.53e-05	0.000358	CcSEcCtD
Emtricitabine—Dizziness—Methotrexate—systemic scleroderma	4.38e-05	0.000346	CcSEcCtD
Emtricitabine—Vomiting—Methotrexate—systemic scleroderma	4.21e-05	0.000333	CcSEcCtD
Emtricitabine—Rash—Methotrexate—systemic scleroderma	4.18e-05	0.00033	CcSEcCtD
Emtricitabine—Dermatitis—Methotrexate—systemic scleroderma	4.17e-05	0.000329	CcSEcCtD
Emtricitabine—Headache—Methotrexate—systemic scleroderma	4.15e-05	0.000328	CcSEcCtD
Emtricitabine—Nausea—Methotrexate—systemic scleroderma	3.93e-05	0.000311	CcSEcCtD
